Aldeyra Therapeutics Announces 2016 Research and Development Day
(firmenpresse) - LEXINGTON, MA -- (Marketwired) -- 09/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will host a Research and Development Day to discuss the company''s late-stage clinical programs in ocular inflammation and inborn errors of aldehyde metabolism. Aldeyra will also provide a summary of recent discussions with the U.S. Food and Drug Administration. Management and speaker presentations will begin at 8:00 a.m. Eastern Time on Monday, September 26, 2016 at the offices of Dechert, LLP in New York City.
A live webcast of the presentation and slide deck will be available via the Company''s Investor Relations website at . Following the live webcast, an archived version will be available on the website until September 25, 2017.
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra''s lead product candidate, NS2, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. NS2 has not been approved for sale in the U.S. or elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 Ext. 205
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.09.2016 - 06:00 Uhr
Sprache: Deutsch
News-ID 1457191
Anzahl Zeichen: 3479
contact information:
Contact person:
Town:
LEXINGTON, MA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 149 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Aldeyra Therapeutics Announces 2016 Research and Development Day
"
steht unter der journalistisch-redaktionellen Verantwortung von
Aldeyra Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
